Research from our group and others has demonstrated that epithelial-mesenchymal transition (EMT) is a central phenomenon occurring in KRAS-mutant lung cancer, which contributes to intracellular tumor heterogeneity, increased metastatic potential, therapeutic resistance to pharmacological agents, and poor patient outcomes (9–11). Here, KRAS is linked to neoplasm.